Fortress Biotech Inc Total Assets
Fortress Biotech Inc total assets. Based on the latest financial reports, Fortress Biotech Inc (FBIO) holds total assets worth $185.55 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Fortress Biotech Inc (FBIO) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Fortress Biotech Inc (2009–2025)
Total assets of Fortress Biotech Inc from 2009 to 2025. This chart illustrates how Fortress Biotech Inc's total assets have evolved over time, based on quarterly financial data. See Fortress Biotech Inc stock quote for real-time trading data and today's change.
Fortress Biotech Inc - Asset Composition Analysis
Fortress Biotech Inc Total Assets Breakdown (December 2025)
Fortress Biotech Inc total assets breakdown as of December 2025. Fortress Biotech Inc's total assets of $185.55 Million consist of 66.7% current assets and 33.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.8% |
| Accounts Receivable | $29.94 Million | 16.1% |
| Inventory | $9.62 Million | 5.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $27.61 Million | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Fortress Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore FBIO working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fortress Biotech Inc's current assets represent 66.7% of total assets in 2025, a decrease from 89.8% in 2009.
- Cash Position: Cash and equivalents constituted 42.8% of total assets in 2025, down from 89.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 16.1% of total assets.
Fortress Biotech Inc Competitors by Total Assets
Key competitors of Fortress Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Fortress Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 1.27 | 5.91 |
| Quick Ratio | 2.30 | 1.06 | 5.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.10 Million | $18.97 Million | $264.17 Million |
Fortress Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Fortress Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 28.7% |
| Total Assets | $185.55 Million |
| Market Capitalization | $64.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fortress Biotech Inc's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fortress Biotech Inc's assets grew by 28.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fortress Biotech Inc (2009–2025)
The table below shows the annual total assets of Fortress Biotech Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $185.55 Million | +28.65% |
| 2024-12-31 | $144.22 Million | -13.91% |
| 2023-12-31 | $167.53 Million | -43.08% |
| 2022-12-31 | $294.30 Million | -25.78% |
| 2021-12-31 | $396.50 Million | +18.92% |
| 2020-12-31 | $333.41 Million | +47.25% |
| 2019-12-31 | $226.42 Million | +60.59% |
| 2018-12-31 | $140.99 Million | -42.67% |
| 2017-12-31 | $245.95 Million | +44.06% |
| 2016-12-31 | $170.73 Million | +43.94% |
| 2015-12-31 | $118.61 Million | +32.78% |
| 2014-12-31 | $89.33 Million | -11.19% |
| 2013-12-31 | $100.58 Million | +145.37% |
| 2012-12-31 | $40.99 Million | +75.37% |
| 2011-12-31 | $23.38 Million | +56.47% |
| 2010-12-31 | $14.94 Million | +785.54% |
| 2009-12-31 | $1.69 Million | -- |
About Fortress Biotech Inc
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalc… Read more